Loading
AXIN1 (Axin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Oesophageal cancer, Skin cancer and 5 more.
Component of the beta-catenin destruction complex required for regulating CTNNB1 levels through phosphorylation and ubiquitination, and modulating Wnt-signalling. Controls dorsoventral patterning via two opposing effects; down-regulates CTNNB1 to inhibit the Wnt signalling pathway and ventralise embryos, but also dorsalises embryos by activating a Wnt-independent JNK signalling pathway. In Wnt signalling, probably facilitates the phosphorylation of CTNNB1 and APC by GSK3B.
Open Targets scores its association with cancer at 0.86 (direct and indirect evidence; datatypes genetic literature 0.61, affected pathway 0.94, literature 0.97, genetic association 0.71, somatic mutation 0.93). IntOGen calls it a driver in 9 cohorts (0 activating, 9 loss-of-function), covering Oesophageal Adenocarcinoma, Glioblastoma Multiforme, Hepatocellular Carcinoma.
In plain words · AXIN1 (Axin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Oesophageal cancer, Skin cancer and 5 more.
AXIN1 (Axin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Oesophageal cancer, Skin cancer and 5 more.
Component of the beta-catenin destruction complex required for regulating CTNNB1 levels through phosphorylation and ubiquitination, and modulating Wnt-signalling.
No product in this corpus aims at AXIN1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 1997. Earliest sequence paper UniProt cites for the protein: Zeng et al, Cell, 1997, "The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation". Source.
Sources: HGNC HGNC:903 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15169 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000103126 (association with cancer (MONDO_0004992) 0.86; per-cancer scores at or above 0.5: hepatocellular carcinoma 0.79, melanoma 0.55, skin cancer 0.55, lung cancer 0.54, leukaemia 0.50 (GraphQL API, CC0)); IntOGen AXIN1 (driver in 9 cohorts (Act 0, LoF 9); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Component of the beta-catenin destruction complex required for regulating CTNNB1 levels through phosphorylation and ubiquitination, and modulating Wnt-signalling. Controls dorsoventral patterning via two opposing effects; down-regulates CTNNB1 to inhibit the Wnt signalling pathway and ventralise embryos, but also dorsalises embryos by activating a Wnt-independent JNK signalling pathway. In Wnt signalling, probably facilitates the phosphorylation of CTNNB1 and APC by GSK3B. Enhances TGF-beta signalling by recruiting the RNF111 E3 ubiquitin ligase and promoting the degradation of inhibitory SMAD7. Also a component of the AXIN1-HIPK2-TP53 complex which controls cell growth, apoptosis and development. Facilitates the phosphorylation of TP53 by HIPK2 upon ultraviolet irradiation. Location: Cytoplasm; Nucleus; Membrane; Cell membrane (UniProt). Locus 16p13.3 (HGNC).
Query for this target: (TITLE:"AXIN1" OR ABSTRACT:"AXIN1" OR TITLE:"axin 1" OR ABSTRACT:"axin 1" OR TITLE:"Axin-1" OR ABSTRACT:"Axin-1" OR TITLE:"PPP1R49" OR ABSTRACT:"PPP1R49") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AXIN1, not a curated reading list.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Skin cancer (all types), IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Skin cancer (all types), IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Skin cancer (all types), IntOGen.
Shares Leukaemia (all types), Oesophageal cancer, Skin cancer (all types), Hepatocellular carcinoma.
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Skin cancer (all types), Hepatocellular carcinoma.
Shares Leukaemia (all types), Skin cancer (all types), Glioma & glioblastoma, IntOGen.
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).